| Active substance | Ravulizumab |
| Holder | Alexion Pharma Belgium |
| Status | Closed |
| Indication | treatment of adult patients with Neuromyelitis Optica Spectrum Disorder (NMOSD) who are anti-aquaporin 4 antibody-positive (AQP4 +) |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update |
09/10/2025 |
Ultomiris
Last updated on